- Home
- FORA vs PRLD Comparison
FORA vs PRLD Comparison
Compare FORA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- PRLD
- Stock Information
- Founded
- FORA 2014
- PRLD 2016
- Country
- FORA United States
- PRLD United States
- Employees
- FORA N/A
- PRLD N/A
- Industry
- FORA Computer Software: Prepackaged Software
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- FORA Technology
- PRLD Health Care
- Exchange
- FORA Nasdaq
- PRLD Nasdaq
- Market Cap
- FORA 62.7M
- PRLD 73.7M
- IPO Year
- FORA N/A
- PRLD 2020
- Fundamental
- Price
- FORA $1.96
- PRLD $0.81
- Analyst Decision
- FORA Strong Buy
- PRLD Strong Buy
- Analyst Count
- FORA 1
- PRLD 2
- Target Price
- FORA $5.00
- PRLD $4.50
- AVG Volume (30 Days)
- FORA 30.3K
- PRLD 279.1K
- Earning Date
- FORA 05-13-2025
- PRLD 05-06-2025
- Dividend Yield
- FORA N/A
- PRLD N/A
- EPS Growth
- FORA N/A
- PRLD N/A
- EPS
- FORA N/A
- PRLD N/A
- Revenue
- FORA $20,153,263.00
- PRLD $7,000,000.00
- Revenue This Year
- FORA $13.31
- PRLD N/A
- Revenue Next Year
- FORA N/A
- PRLD N/A
- P/E Ratio
- FORA N/A
- PRLD N/A
- Revenue Growth
- FORA N/A
- PRLD N/A
- 52 Week Low
- FORA $1.85
- PRLD $0.61
- 52 Week High
- FORA $4.03
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- FORA 46.06
- PRLD 57.52
- Support Level
- FORA $1.90
- PRLD $0.71
- Resistance Level
- FORA $2.08
- PRLD $0.72
- Average True Range (ATR)
- FORA 0.12
- PRLD 0.08
- MACD
- FORA 0.02
- PRLD 0.02
- Stochastic Oscillator
- FORA 41.02
- PRLD 76.92
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.